Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Nilsine Partners LLC

Nilsine Partners LLC boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 3.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,876 shares of the medical equipment provider’s stock after purchasing an additional 1,361 shares during the period. Nilsine Partners LLC’s holdings in Hologic were worth $3,091,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in HOLX. Prentiss Smith & Co. Inc. grew its position in shares of Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after acquiring an additional 130 shares during the last quarter. Covestor Ltd grew its position in Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 133 shares during the last quarter. First Horizon Advisors Inc. increased its stake in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares during the period. Brooklyn Investment Group raised its holdings in shares of Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after buying an additional 145 shares during the last quarter. Finally, Empirical Finance LLC boosted its position in shares of Hologic by 1.8% during the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after buying an additional 147 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

NASDAQ HOLX opened at $72.81 on Tuesday. The company has a market cap of $16.43 billion, a P/E ratio of 21.86, a P/E/G ratio of 2.43 and a beta of 0.97. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 1 year low of $68.61 and a 1 year high of $84.67. The company has a fifty day simple moving average of $73.89 and a 200 day simple moving average of $78.25.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. The business had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.89 EPS. On average, sell-side analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

Analysts Set New Price Targets

HOLX has been the topic of several analyst reports. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. UBS Group lifted their target price on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Citigroup lowered Hologic from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $95.00 to $85.00 in a research note on Tuesday, October 1st. Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a research report on Monday, January 13th. Finally, Morgan Stanley reduced their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Seven analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $88.92.

Insider Activity

In other news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.88% of the stock is owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.